Semaglutide Cuts Kidney Disease Risk by 24% in Type 2 Diabetes
Highlights: Semaglutide, in the FLOW trial, significantly reduces kidney disease progression in type 2 diabetes patients by 24% Confirmatory secondary endpoints reinforce semaglutide’s...